Document Detail


Folate-PEG-Appended Dendrimer Conjugate with α-Cyclodextrin as a Novel Cancer Cell-Selective siRNA Delivery Carrier.
MedLine Citation:
PMID:  22873579     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
We previously reported that of the various polyamidoamine (PAMAM) STARBURST dendrimer (generation 3, G3) (dendrimer) conjugates with cyclodextrins (CyDs), the dendrimer (G3) conjugate with α-CyD having an average degree of substitution of 2.4 (α-CDE (G3)) has the greatest potential for a novel carrier for siRNA in vitro and in vivo. To improve the siRNA transfer activity and the lack of target specificity of α-CDE (G3), we prepared folate-polyethylene glycol (PEG)-appended α-CDEs (G3) (Fol-PαCs) with various degrees of substitution of folate (DSF) and evaluated their siRNA transfer activity to folate receptor (FR)-overexpressing cancer cells in vitro and in vivo. Of the three Fol-PαCs (G3, DSF 2, 4 and 7), Fol-PαC (G3, DSF 4) had the highest siRNA transfer activity in KB cells (FR-positive). Fol-PαC (G3, DSF 4) was endocytosed into KB cells through FR. No cytotoxicity of the siRNA complex with Fol-PαC (G3, DSF 4) was observed in KB cells (FR-positive) or A549 cells (FR-negative) up to the charge ratio of 100/1 (carrier/siRNA). In addition, the siRNA complex with Fol-PαC (G3, DSF 4) showed neither interferon response nor inflammatory response. Importantly, the siRNA complex with Fol-PαC (G3, DSF 4) tended to show the in vivo RNAi effects after intratumoral injection and intravenous injection in tumor cells-bearing mice. The FITC-labeled siRNA and TRITC-labeled Fol-PαC (G3, DSF 4) were actually accumulated in tumor tissues after intravenous injection in the mice. In conclusion, the present results suggest that Fol-PαC (G3, DSF 4) could potentially be used as a FR-overexpressing cancer cell-selective siRNA delivery carrier in vitro and in vivo.
Authors:
Hidetoshi Arima; Ayumi Yoshimatsu; Haruna Ikeda; Ayumu Ohyama; Keiichi Motoyama; Taishi Higashi; Akira Tsuchiya; Takuro Niidome; Yoshiki Katayama; Kenjiro Hattori; Tomoko Takeuchi
Related Documents :
7967639 - Specifying epigenetic states with autoregulatory transcription factors.
2004419 - Dna methylation inhibits transcription indirectly via a methyl-cpg binding protein.
11280769 - Oct-2 and bob-1 deficiency in hodgkin and reed sternberg cells.
2948109 - Cellular promoters incorporated into the adenovirus genome: effects of viral regulatory...
17513589 - Expression of reductive dehalogenase genes in dehalococcoides ethenogenes strain 195 gr...
17967179 - A novel activating role of src and stat3 on hgf transcription in human breast cancer ce...
19951729 - Delivery of rifampicin-plga microspheres into alveolar macrophages is promising for tre...
2624869 - Identification of peanut agglutinin receptors on mouse testicular germ cells.
25202359 - Inflammatory suppressive effect of prostate cancer cells with prolonged exposure to tra...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-9
Journal Detail:
Title:  Molecular pharmaceutics     Volume:  -     ISSN:  1543-8392     ISO Abbreviation:  Mol. Pharm.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-8-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101197791     Medline TA:  Mol Pharm     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University , 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Exploring uncharted territories: predicting activity cliffs in structure-activity landscapes.
Next Document:  A case-control study of occupation/industry and renal cell carcinoma risk.